A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer

Huang, Jianda; Gu, Tongjie; Ying, Jun

doi:10.1007/s10147-017-1159-1

Cited by 13 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Why moderate increases in circulating ALP are also associated with higher lung cancer incidence is unclear. One possibility might be that high ALP levels appear to be independent predictors for bone metastases that are commonly detected in patients with lung cancer 33 34. Thus, high ALP levels might be associated with lung cancer risk due to these unrecognised bone metastases years prior to a cancer diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Circulating liver enzymes and risks of chronic diseases and mortality in the prospective EPIC-Heidelberg case-cohort study

et al. 2020

View full text Add to dashboard Cite

ObjectivesElevated liver enzyme concentrations in blood are indicative of liver diseases and may provide an early signal for being at risk for other chronic diseases. Our study aimed to assess the relationships of alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate transaminase (AST) and the De Ritis ratio (AST/ALT) with incidence and mortality of cardiovascular diseases (CVD) and the four most common cancers, that is, breast, prostate, colorectal and lung.Setting, participants and outcome measuresWe analysed a case-cohort sample of the prospective European Prospective Investigation into Cancer and Nutrition-Heidelberg cohort, including cancer (n=1632), cancer mortality (n=761), CVD (n=1070), CVD mortality (n=381) and a random subcohort (n=2739) with an average follow-up duration of 15.6 years. Concentrations of liver enzymes were measured in prediagnostic blood samples and Prentice-weighted Cox regression models were used to estimate HRs with 95% CIs.ResultsHigh ALP levels were associated with increased risk for lung cancer and all-cause mortality (highest vs lowest quartile, multivariable adjusted HR=2.39 (95% CI 1.30 to 4.39), HR=1.31 (95% CI 1.02 to 1.67)), high AST levels with all-cause mortality (HR=1.45 (95% CI 1.15 to 1.82)), and a high De Ritis ratio with prostate cancer risk, all-cause and cancer mortality (HR=1.61 (95% CI 1.10 to 2.36), HR=1.60 (95% CI 1.25 to 2.04), HR=1.67 (95% CI 1.26 to 2.23)). Using cut-points for liver enzyme levels above normal, we observed positive associations for all-cause mortality with ALP, GGT and AST, and assigning a combined risk score resulted in positive associations with all-cause and cause-specific mortality.ConclusionsMeasurements of serum liver enzymes, as routinely performed in health check-ups, may support the identification of individuals at increased risk for all-cause mortality. Further prospective studies are needed to verify our first results on individual cancers and on a combined risk score.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating liver enzymes and risks of chronic diseases and mortality in the prospective EPIC-Heidelberg case-cohort study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Serum concentrations of TRACP were found increased in patients with bone metastases from breast cancer, but not lung cancer (90,155). In prostate cancer, high NTX and CTX levels were associated with bone metastases (35).…”

Section: Diagnosis Of Bone Metastasismentioning

confidence: 92%

“…Furthermore, a meta-analysis including 19 trials and 3,628 patients with solid tumors showed that serum BALP levels in patients with bone metastases were 2.9-fold higher (P < 0.05) than in patients without bone lesions (91). Another meta-analysis in lung cancer including 16 trials and 1,720 patients with or without bone metastases showed that high concentrations of BALP were also associated with bone metastasis (155).…”

Section: Diagnosis Of Bone Metastasismentioning

confidence: 99%

See 1 more Smart Citation

Bone metastasis: mechanisms, therapies, and biomarkers

Clézardin

Coleman

Puppo

et al. 2021

Physiological Reviews

235

160

View full text Add to dashboard Cite

Skeletal metastases are frequent complications of many cancers, causing bone complications (fractures, bone pain, disability), which negatively affect the patient's quality of life. Here, we first discuss the burden of skeletal complications in cancer bone metastasis. We then describe the pathophysiology of bone metastasis. Bone metastasis is a multistage process; long before the development of clinically detectable metastases, circulating tumor cells settle and enter a dormant state in normal vascular and endosteal niches present in the bone marrow, which provide immediate attachment and shelter, and only become active years later as they proliferate and alter the functions of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells, promoting skeletal destruction. The molecular mechanisms involved in mediating each of these steps are described and we also explain how tumor cells interact with a myriad of interconnected cell populations in the bone marrow, including a rich vascular network, immune cells, adipocytes and nerves. We discuss metabolic programs that tumor cells could engage with to specifically grow in bone. We also describe the progress and future directions of existing bone-targeted agents and report emerging therapies that have arisen from recent advances in our understanding of the pathophysiology of bone metastases. Finally, we discuss the value of bone turnover biomarkers in detection and monitoring of progression and therapeutic effects in patients with bone metastasis.

show abstract

“…32 Recent study of meta-analysis showed the clinical significance of bone turnover markers such as total alkaline phosphatase, BAP, ICTP and NTX for the diagnosis of bone metastasis in lung cancer, but TRACP-5b was not correlated. 33 In our study, high early post treatment ICTP was associated with progression of bone disease, SREs and increasing risk of death after treatment with the bone modifying agents for lung cancer bone metastasis. Although the situation is different, both have shown the usefulness of ICTP in lung cancer bone metastasis.…”

Section: Discussionmentioning

confidence: 50%

Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

Urakawa

Ando

Hase

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Bone modifying agents (BMAs) have become a standard treatment to prevent skeletal-related events (SREs) in bone metastases (BMs). The aim of our study is to determine the clinical value of serum bone resorption markers for predicting clinical outcomes after using BMAs in patients with BM. Patients were enrolled between May 2013 and October 2017 at the Nagoya University Hospital, Japan. We prospectively observed changes in pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and tartrate-resistant acid phosphatase 5b (TRACP-5b) during treatment with BMAs. The relationship between serum markers before and after treatment and clinical outcomes such as progression of bone disease (BD), SREs and overall survival (OS) were evaluated. Pearson chi-square test and Kaplan-Meier product limit methods were used for analysis. Sixty-seven patients were analyzed. The primary tumor sites were 21 lung, 16 breast and 30 others. Forty and 27 patients were treated with Denosumab and Zoledronic acid, respectively. Progression of BDs, SREs and death were observed in 10, 16 and 31 cases, respectively. The median follow-up period after using BMAs was 12.3 (range 0.3-66.3) months. ICTP at 3-4 weeks was significantly correlated with increasing BD progression, SREs and death after treatment in both the whole and lung cancer cohorts. Base line ICTP and TRACP-5b were also associated with increasing BD progression in the whole cohort. Our study showed that early posttreatment ICTP is useful for predicting BD progression, SREs and OS after use of BMAs in patients with BM and even in patients with lung cancer BM.Additional Supporting Information may be found in the online version of this article.

show abstract

A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer

Abstract: The present meta-analysis suggested that serum measurement of TALP, BALP, ICTP and NTX might be helpful in detecting BM in lung cancer.

Cited by 13 publications

References 35 publications

Circulating liver enzymes and risks of chronic diseases and mortality in the prospective EPIC-Heidelberg case-cohort study

Circulating liver enzymes and risks of chronic diseases and mortality in the prospective EPIC-Heidelberg case-cohort study

Bone metastasis: mechanisms, therapies, and biomarkers

Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

Contact Info

Product

Resources

About